

Edgar Filing: Capstone Therapeutics Corp. - Form 8-K

Capstone Therapeutics Corp.  
Form 8-K  
June 18, 2012  
UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K  
CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

---

Date of Report: June 15, 2012 (Date of earliest event reported)

CAPSTONE THERAPEUTICS CORP.  
(Exact name of registrant as specified in its charter)

|                                                               |                                       |                                                       |
|---------------------------------------------------------------|---------------------------------------|-------------------------------------------------------|
| Delaware<br>(State or other jurisdiction of<br>incorporation) | 000-21214<br>(Commission File Number) | 86-0585310<br>(I.R.S. Employer<br>Identification No.) |
|---------------------------------------------------------------|---------------------------------------|-------------------------------------------------------|

|                                                                                                    |                     |
|----------------------------------------------------------------------------------------------------|---------------------|
| 1275 West Washington Street, Suite 101, Tempe, Arizona<br>(Address of principal executive offices) | 85281<br>(Zip Code) |
|----------------------------------------------------------------------------------------------------|---------------------|

Registrant's telephone number, including area code:  
(602) 286-5520

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Section 5 - Corporate Governance and Management

Item 5.07. Submission of Matters to a Vote of Security Holders.

Annual Meeting of Stockholders

(a) Our Annual Meeting of Stockholders was held on June 15, 2012 with a quorum in attendance.

(b) At the Annual Meeting, stockholders elected our nominee for Class III Director and ratified the appointment of Moss Adams LLP as our independent registered public accounting firm for the fiscal year ended December 31, 2012. The certified results of the matters voted upon at the meeting, which are more fully described in our Proxy Statement, are as follows:

Proposal 1: Proposal to Elect a Class III Director For Term Expiring in Year 2015:

| Nominee Name         | Number of Shares |           |                  |
|----------------------|------------------|-----------|------------------|
|                      | For              | Withheld  | Broker Non-Votes |
| Elwood D. Howse, Jr. | 11,506,853       | 2,069,733 | 18,260,885       |

Proposal 2: Proposal to Ratify the Appointment of Moss Adams LLP as our Independent Registered Public Accounting Firm for Fiscal Year 2012

|  | Number of Shares |         |         |
|--|------------------|---------|---------|
|  | For              | Against | Abstain |
|  | 35,545,382       | 792,341 | 23,718  |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CAPSTONE THERAPEUTICS CORP.

Dated: June 18, 2012

/s/ John M. Holliman, III  
John M. Holliman, III  
Executive Chairman